Ascelia Pharma publishes Orviglance liver MRI contrast agent study in JMRI
Bitget2026/09/24 05:30- Ascelia Pharma announced publication of a peer-reviewed Orviglance clinical study in the Journal of Magnetic Resonance Imaging.
- Results were already presented via the journal article, not flagged for a future medical meeting.
- Study assessed a single oral dose in adults with hepatic impairment versus those without impairment.
- Publication supports Orviglance’s differentiated profile as a manganese-based liver MRI contrast agent, reinforcing its clinical development rationale.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
